Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7261 to 7275 of 7688 results

  1. Tocilizumab for the treatment of rheumatoid arthritis (TA198)

    This guidance has been updated and replaced by NICE technology appraisal guidance 247.

    Technology appraisal guidance
    Published
    25 August 2010

  2. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    24 February 2010

  3. Laparoscopic surgery for colorectal cancer (TA17)

    This guidance has been replaced by NICE technology appraisal guidance 105. 

    Technology appraisal guidance
    Published
    16 December 2000

  4. Cetuximab for the treatment of recurrent and/or metastatic squamous cell cancer of the head and neck (TA172)

    This guidance has been updated and replaced by NICE technology appraisal guidance 473.

    Technology appraisal guidance
    Published
    24 June 2009

  5. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura (TA205)

    This guidance has been updated and replaced by NICE technology appraisal guidance 293.

    Technology appraisal guidance
    Published
    27 October 2010

  6. Diabetes (type 2) - pioglitazone (TA21)

    This guidance has been replaced by NICE technology appraisal guidance 63 [Replaced by NICE guideline CG66].

    Technology appraisal guidance
    Published
    27 March 2001

  7. Sorafenib for the treatment of advanced hepatocellular carcinoma (TA189)

    This guidance has been replaced by NICE technology appraisal guidance 474.

    Technology appraisal guidance
    Published
    26 May 2010

  8. Erlotinib for the treatment of non-small-cell lung cancer (TA162)

    This guidance has been updated and replaced by NICE technology appraisal guidance 374.

    Technology appraisal guidance
    Last updated
    1 December 2012

  9. Febuxostat for the management of hyperuricaemia in people with gout (TA164)

    This guidance has been updated and replaced by NICE guideline NG219.

    Technology appraisal guidance
    Published
    17 December 2008

  10. Cochlear implants for children and adults with severe to profound deafness (TA166)

    This guidance has been updated and replaced by NICE technology appraisal guidance 566.

    Technology appraisal guidance
    Published
    28 January 2009

  11. Endovascular stent–grafts for the treatment of abdominal aortic aneurysms (TA167)

    This guidance has been updated and replaced by NICE guideline NG156.

    Technology appraisal guidance
    Published
    25 February 2009

  12. Autologous cartilage transplantation for full thickness cartilage defects in knee joints (TA16)

    This guidance has been replaced by NICE technology appraisal guidance 89 [Replaced by NICE technology appraisal guidance 477].

    Technology appraisal guidance
    Published
    16 December 2000

  13. Ezetimibe for the treatment of primary (heterozygous-familial and non-familial) hypercholesterolaemia (TA132)

    This guidance has been updated and replaced by NICE technology appraisal guidance 385.

    Technology appraisal guidance
    Published
    28 November 2007

  14. Omalizumab for severe persistent allergic asthma (TA133)

    This guidance has been replaced by NICE technology appraisal guidance 278.

    Technology appraisal guidance
    Published
    28 November 2007

  15. Glycoprotein IIb/IIIa inhibitors in the treatment of acute coronary syndromes (TA12)

    This guidance has been replaced by NICE technology appraisal guidance 47. 

    Technology appraisal guidance
    Published
    26 September 2000